SAR.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 04:44):

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases...

Stats
Today's Volume	1.40M
Average Volume	1.24M
Market Cap	26.69M
EPS	£0 ( 2024-03-27 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-4.38
ATR14	£0.267 (1.02%)

Volume Correlation

Long: 0.12 (neutral)

Short: 0.73 (moderate)

Signal:(43.741) Neutral

Sareum Holdings PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sareum Holdings PLC Correlation - Currency/Commodity

-0.14
( neutral )

-0.05
( neutral )

-0.21
( neutral )

0.05
( neutral )

-0.06
( neutral )

0.35
( neutral )

Sareum Holdings PLC Financials

Annual	2022
Revenue:	£0
Gross Profit:	£-1 000.00 (0.00 %)
EPS:	£-0.0469

FY	2022
Revenue:	£0
Gross Profit:	£-1 000.00 (0.00 %)
EPS:	£-0.0469

FY	2022
Revenue:	£0
Gross Profit:	£0 (0.00 %)
EPS:	£-0.0321

FY	2021
Revenue:	£0.00
Gross Profit:	£0.00 (0.00 %)
EPS:	£-0.0265

Financial Reports:

No articles found.

Sareum Holdings PLC

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.